Skip to main content
Succinylacetone and succinylacetoacetate are responsible for the observed liver and kidney toxicity in patients with tyrosinemia type 1, rare pediatric disease causing progressive liver failure and liver cancer in young children.
Tyrosinemia type I occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine catabolic pathway. In patients with tyrosinemia type I, catabolic intermediates maleylacetoacetate and fumarylacetoacetate are converted to the toxic metabolites succinylacetone and succinylacetoacetate. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of tyrosinemia type I
Seattle Children’s provides healthcare without regard to race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry) or disability. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.
© 1995-2014 Seattle Children’s Hospital